About

Jens-Ole Bock, M.Sc.

Co-founder

Jens-Ole Bock has more than 20 years of commercial experience in the life sciences, working with some of the world’s earliest and leading genome-editing companies. As part of the specialist team at Sigma-Aldrich, he introduced the first commercially available genome-editing tool, the Zinc Finger Nuclease (ZFN), to the European market. During this period, he built one of the company’s fastest-growing life-science business segments and delivered more than 100 presentations across Europe, the United States, and Asia.

In 2017, Bock founded COBO Technologies to meet the growing demand for high-quality genome-editing analytics. The company specializes in genome-editing quality control, with particular expertise in InDel mutation analysis and proteomic profiling for customers worldwide. Since 2022, Bock has served on the board, providing strategic and commercial guidance.

In 2019, Bock founded CRISPR Medicine News (CMN), now part of CRISPR Medicine Media ApS. CMN has grown into a leading global news and intelligence platform covering CRISPR and genetic medicine, including gene-editing technologies, delivery systems, clinical development, and safety innovation. Managed by a skilled editor team, CMN delivers weekly newsletters, briefings, webinars, and clinical-trial updates. In 2026, CMN will launch the CMN Intelligence platform, providing global trial tracking, analytical reports, and data-infrastructure services.

Bock also established the CRISPRMED conference series, now the world’s largest conference dedicated to CRISPR medicine. Following its launch in Copenhagen in 2024, CRISPRMED has grown rapidly, with annual events in Copenhagen and planned global expansion in 2026, including its first international meeting in Brazil. The conferences bring together scientists, clinicians, industry leaders, regulators, investors, and patient advocates, and include dedicated initiatives for early-career researchers such as the WeDoCRISPR Flash Talk Competition.

In addition, Bock convened the pan-European non-profit EGMEDC (European Genome Medicine Development Consortium), scheduled to launch in April 2026 to strengthen European collaboration in genome medicine development.

Across his career, Jens-Ole Bock has played a central role in building a global CRISPR medicine ecosystem. By founding and supporting complementary platforms spanning analytics, media, data intelligence, international convening, and non-profit collaboration, he has helped connect research, community building, and actionable intelligence - supporting collaboration, transparency, and informed decision-making across the full CRISPR value chain.

Contact details: jbock@cobotechnologies.com

Hasse Herlevsen, M. Sc.

COO | Co-owner

Hasse Herlevsen has worked more than 30 years in Big Pharma, Mid-size Pharma & Small Biotech within Quality, Development, Operations & Laboratories. He has comprehensive biotech and pharma industry business experience - many years in high-level positions e.g. 9 years as Corporate Vice President in LEO Pharma, Global Quality & Environment, Health & Safety, where he was responsible for Global Quality (GMP, GCP, GLP, GDP & QA for Pharmacovigilance). Here he was head of 200 people in 6 different countries. In addition, he is a founder of small start-up companies.

Contact details: hh@cobotechnologies.com | +45 25300903

Eric Paul Bennett, M.Sc., Dr. Med.

Scientific Advisor | Co-founder

Eric P. Bennett has obtained both his master degree in Biochemistry and Molecular Biology (MSc) and doctoral degree (Dr.med) from the University of Copenhagen, Denmark. His research efforts were initiated at the Copenhagen Center for Glycomics (University of Copenhagen), where he the last 9 years has been focusing on ways of establishing precision-engineered isogenic cells lacking individual glycogenes. Using the recently emerged nuclease targeting technologies, such as ZFN, TALEN and CRISPR/Cas9, these efforts have among others led to establishment of novel methodologies that both improve the targeting and indel detection efficacy of precise gene editing. He is co-inventor of multiple patents and patent applications, that also cover the indel detection methodology named IDAA. Eric has published 100+ papers and is a renowned expert and speaker on targeted gene editing technology. Eric serves as a scientific advisor for Cobo Technologies.

Contact details: epbennett@cobotechnologies.com | +45 40196295